University Hospitals Seidman Cancer, Case Comprehensive Cancer Center
Welcome,         Profile    Billing    Logout  
 8 Trials 
14 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Brunstein, Claudio G
NCT06129734: Decitabine and Venetoclax Treatment as Maintenance Therapy in Patients Post Allograft Stem Cell Transplant

Not yet recruiting
1/2
20
US
Venetoclax, Decitabine
Benjamin Tomlinson
Myeloid Malignancy, Acute Myeloid Leukemia
12/25
12/26
NCT01962636: Umbilical Cord Blood Transplantation Using a Myeloablative Preparative Regimen for Hematological Diseases

Recruiting
N/A
200
US
Fludarabine, Fludara, Cyclophosphamide, Cytoxan, Total Body Irradiation, Cyclosporine A, CSA, Mycophenylate mofetil, MMF, Umbilical cord blood, UCB
Masonic Cancer Center, University of Minnesota
Acute Myeloid Leukemia (AML), Acute Lymphocytic Leukemia (ALL), Chronic Myelogenous Leukemia, Plasma Cell Leukemia, Myelofibrosis, Myelodysplasia, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Marginal Zone B-Cell Lymphoma, Follicular Lymphoma, Lymphoplasmacytic Lymphoma, Mantle-Cell Lymphoma, Prolymphocytic Leukemia, Diffuse Large B Cell Lymphoma, Lymphoblastic Lymphoma, Burkitt's Lymphoma, Non-Hodgkin Lymphoma, Multiple Myeloma
10/25
10/26
NCT01451502: Infusion of Cell Populations From Unlicensed Umbilical Cord Blood Units

Recruiting
N/A
250
US
Umbilical Cord Blood (UCB)
Masonic Cancer Center, University of Minnesota
Lymphatic Diseases, Hematopoietic Malignancy
12/25
12/25
Tomlinson, Benjamin K
STIMULUS MDS-US, NCT04878432: : Sabatolimab Added to HMA in Higher Risk MDS

Completed
2
39
US
MBG453, sabatolimab, Azacitidine, Decitabine, INQOVI (oral decitabine)
Novartis Pharmaceuticals
Myelodysplastic Syndrome (MDS)
09/23
09/24
MyeloMATCH, NCT05564390: MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH ( Screening Trial)

Recruiting
2
2000
Canada, US
Azacitidine, 5 AZC, 5-AC, 5-Azacitidine, 5-Azacytidine, 5-AZC, Azacytidine, Azacytidine, 5-, Ladakamycin, Mylosar, U-18496, Vidaza, Best Practice, standard of care, standard therapy, Biopsy, BIOPSY_TYPE, Bx, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Biopsy of Bone Marrow, Biopsy, Bone Marrow, Cytarabine, .beta.-Cytosine arabinoside, 1-.beta.-D-Arabinofuranosyl-4-amino-2(1H)pyrimidinone, 1-.beta.-D-Arabinofuranosylcytosine, 1-Beta-D-arabinofuranosyl-4-amino-2(1H)pyrimidinone, 1-Beta-D-arabinofuranosylcytosine, 1.beta.-D-Arabinofuranosylcytosine, 2(1H)-Pyrimidinone, 4-Amino-1-beta-D-arabinofuranosyl-, 2(1H)-Pyrimidinone, 4-amino-1.beta.-D-arabinofuranosyl-, Alexan, Ara-C, ARA-cell, Arabine, Arabinofuranosylcytosine, Arabinosylcytosine, Aracytidine, Aracytin, Aracytine, Beta-Cytosine Arabinoside, CHX-3311, Cytarabinum, Cytarbel, Cytosar, Cytosine Arabinoside, Cytosine-.beta.-arabinoside, Cytosine-beta-arabinoside, Erpalfa, Starasid, Tarabine PFS, U 19920, U-19920, Udicil, WR-28453, Daunorubicin Hydrochloride, Cerubidin, Cerubidine, Cloridrato de Daunorubicina, Daunoblastin, Daunoblastina, Daunoblastine, Daunomycin Hydrochloride, Daunomycin, hydrochloride, Daunorubicin.HCl, Daunorubicini Hydrochloridum, FI-6339, Ondena, RP-13057, Rubidomycin Hydrochloride, Rubilem, Decitabine and Cedazuridine, ASTX 727, ASTX-727, ASTX727, C-DEC, CDA Inhibitor E7727/Decitabine Combination Agent ASTX727, Cedazuridine/Decitabine Combination Agent ASTX727, Cedazuridine/Decitabine Tablet, DEC-C, Inaqovi, Inqovi, Echocardiography, EC, Enasidenib, AG 221, AG-221, AG221, CC-90007 Free Base, Gilteritinib, ASP 2215, ASP-2215, ASP2215, Liposome-encapsulated Daunorubicin-Cytarabine, CPX 351, CPX-351, CPX351, Cytarabine and Daunorubicin Liposomal, Cytarabine-Daunorubicin Liposome for Injection, Daunorubicin and Cytarabine (Liposomal), Liposomal AraC-Daunorubicin CPX-351, Liposomal Cytarabine-Daunorubicin, Liposome-encapsulated Combination of Daunorubicin and Cytarabine, Vyxeos, Multigated Acquisition Scan, Blood Pool Scan, Equilibrium Radionuclide Angiography, Gated Blood Pool Imaging, Gated Heart Pool Scan, MUGA, MUGA Scan, Multi-Gated Acquisition Scan, Radionuclide Ventriculogram Scan, Radionuclide Ventriculography, RNV Scan, RNVG, SYMA Scanning, Synchronized Multigated Acquisition Scanning, Mutation Carrier Screening, Venetoclax, ABT 199, ABT-0199, ABT-199, ABT199, GDC 0199, GDC-0199, GDC0199, RG7601, Venclexta, Venclyxto
National Cancer Institute (NCI)
Acute Myeloid Leukemia, Myelodysplastic Syndrome
05/29
05/29
NCT06129734: Decitabine and Venetoclax Treatment as Maintenance Therapy in Patients Post Allograft Stem Cell Transplant

Not yet recruiting
1/2
20
US
Venetoclax, Decitabine
Benjamin Tomlinson
Myeloid Malignancy, Acute Myeloid Leukemia
12/25
12/26
NCT03434769: AntiCD19 Chimeric Antigen Receptor T Cells for Relapsed or Refractory Non Hodgkin Lymphoma

Active, not recruiting
1
31
US
Cyclophosphamide, Cytoxan, Endoxan, Neosar, Procytox, Revimmune, Cycloblastin, Fludarabine, Fludara, CAR-T Cells
Benjamin Tomlinson
Non-Hodgkin Lymphoma
03/23
02/36
NCT04477291: A Study of CG-806 in Patients With Relapsed or Refractory AML or Higher-Risk MDS

Active, not recruiting
1
80
US
CG-806
Aptose Biosciences Inc.
Acute Myeloid Leukemia, Myelodysplastic Syndromes
12/24
05/25
NCT03955783: Venetoclax and Selinexor in Treating Patients with Relapsed or Refractory High Risk Hematologic Malignancies

Completed
1
78
US
Venetoclax, Selinexor
Sanjay Mohan, Karyopharm Therapeutics Inc, AbbVie
Diffuse Large B-cell Lymphoma, Acute Myeloid Leukemia, Non-Hodgkin's Lymphoma
09/24
09/24
NCT04732845: Human AntiCD19 Chimeric Antigen Receptor T Cells for Relapsed or Refractory Lymphoid Malignancies

Suspended
1
36
US
Fully human anti CD19 CAR-T Cell Dose, Fludarabine, Fludara, Cyclophosphamide, Cytoxan, Endoxan, Neosar, Procytox, Revimmune, Cycloblastin
Benjamin Tomlinson
Non Hodgkin Lymphoma, Acute Lymphoblastic Leukemia, Chronic Lymphocytic Leukemia
03/25
12/39
NCT04187703: 5-Azacitidine and Decitabine Epigenetic Therapy for Myeloid Malignancies

Recruiting
1
20
US
5-azacytidine, azacytidine, Decitabine, 5-aza-2'-deoxycytydine
Benjamin Tomlinson
Myelodysplastic Syndromes, MDS/MPN Crossover Syndromes
12/25
12/26
SGNS70-101, NCT04227847: A Safety Study of SEA-CD70 in Patients With Myeloid Malignancies

Recruiting
1
140
Europe, US
SEA-CD70, azacitidine, VIDAZA
Seagen Inc.
Myelodysplastic Syndrome, Acute Myeloid Leukemia
12/24
11/26
NCT05787496: A Safety, Tolerability and Efficacy Study of NC525 in Subjects with Advanced Myeloid Neoplasms

Active, not recruiting
1
63
US
NC525
NextCure, Inc.
Relapsed or Refractory Acute Myeloid Leukemia, Relapsed or Refractory Chronic Myelomonocytic Leukemia, Relapsed or Refractory Myelodysplastic Syndrome
05/25
05/25
Ignatz-Hoover, James
NCT06129734: Decitabine and Venetoclax Treatment as Maintenance Therapy in Patients Post Allograft Stem Cell Transplant

Not yet recruiting
1/2
20
US
Venetoclax, Decitabine
Benjamin Tomlinson
Myeloid Malignancy, Acute Myeloid Leukemia
12/25
12/26

Download Options